Thyrocare Technologies Limited, established in 2000, stands as a prominent pan-India diagnostic chain offering extensive medical diagnostic services. By March 2022, the company provided over 700 distinct tests, focusing on early detection and management of various disorders, including thyroid, growth, metabolic, and cardiovascular disorders, among others. Thyrocare operates through a centralized processing laboratory (CPL) in Navi Mumbai, supported by 25 regional processing laboratories (RPLs) across major Indian cities, ensuring efficient sample processing. The company also boasts a vast network of around 1500 channel partners and 9000 collection points nationwide.
The fully owned subsidiary, Nueclear Healthcare Limited, enhances Thyrocare's services with PET-CT imaging diagnostics, operating 10 PET-CT scanners across 8 centers in India. Thyrocare's growth is driven by its focus on preventive care, brand recognition through its 'Aarogyam' suite, and strategic acquisitions, such as the associate company Equinox Labs. Despite challenges posed by the COVID-19 pandemic, the company has continued to expand its test offerings and infrastructure, indicating resilience and adaptability in its business model. In 2021, Docon Technologies acquired a 71.22% stake, making Thyrocare its subsidiary.
